Sanara MedTech Q2 revenue up 28% to $25.8M; launches strategic review for Tissue Health Plus subsidiary

Sanara MedTech Inc.

2025-Q2 EPS reported -$0.64 vs consensus -$0.45 ▼ miss (-42.6%)

Net revenue $25.8M, up 28% YoY; net loss narrowed to $2.0M from $3.5M.
Adjusted EBITDA $2.7M vs $0.6M in prior-year quarter.
H1 2025: revenue $49.3M (+27%), net loss $5.5M, adjusted EBITDA $3.3M.
Sanara Surgical segment H1 adjusted EBITDA $7.4M vs $2.5M; THP segment adjusted EBITDA -$4.1M vs -$1.6M.
Company initiates process to evaluate strategic alternatives for Tissue Health Plus subsidiary.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.